The history and accomplishments of the ICGG Gaucher registry

American Journal of Hematology

Volumn 90, Issue S1, 2015, Pages S2-S5

  Weinreb, Neal J ^a   Kaplan, Paige ^b  

^a University Research Foundation for Lysosomal Storage Disorders   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGLUCERASE; BETA GLUCOSIDASE; IMIGLUCERASE;

ANEMIA; BONE DISEASE; CLINICAL TRIAL (TOPIC); DISEASE REGISTRY; DISEASE SEVERITY; EDITORIAL; GAUCHER DISEASE; HEPATOMEGALY; HUMAN; LEUKOPENIA; PATIENT; PATIENT CARE; PRIORITY JOURNAL; RARE DISEASE; SOUTH AND CENTRAL AMERICA; THROMBOCYTOPENIA; WORK; PATHOLOGY; REGISTER;

GAUCHER DISEASE; HUMANS; REGISTRIES;

EID: 84932119715     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24054     Document Type: Editorial

References (44)

1. Grabowski GA, Kolodny EH, Weinreb NJ, et al. Gaucher Disease: Phenotypic and Genetic Variation. In: Valle D, Beaudet AL, Vogelstein B, et al., editors. New York, NY: McGraw-Hill; 2014. http://ommbid.mhmedical.com/content.aspx?bookid=971§ionid=62643794. Accessed June 03, 2015.
2. Lee RE. The pathology of Gaucher disease. Prog Clin Biol Res 1982:177-217.
3. Weinreb NJ, Lee RE. Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher disease who were never treated with enzyme replacement therapy. Crit Rev Oncog 2013;18:177-195.
4. Weinreb NJGJ, Villalobos J, Charrow J, et al. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis 2013;36:543-553.
5. Jones SJE, Prasad S. Disease registries and outcomes research in children: focus on lysosomal storage disorders. Paediatr Drugs 2011;13:33-47.
6. AfHRaQ (US). Registries for Evaluating Patient Outcomes: A User's Guide. Rockville, MD; 2010.
7. Hollak CEAJ, Aymé S, Manuel J. Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. Orphanet J Rare Dis 2011;6:16.
8. Charrow J, Andersson HC, Kaplan P, et al. The Gaucher Registry: Demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000;160:2835-2843.
9. Charrow J, Esplin JA, Gribble TJ, et al. Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med 1998;158:1754-1760.
10. Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 2004;41:15-22.
11. Sobreira E, Pires RF, Cizmarik M, et al. Phenotypic and genotypic heterogeneity in Gaucher disease type 1: A comparison between Brazil and the rest of the world. Mol Genet Metab 2007;90:81-86.
12. Drelichman G, Linares A, Villalobos J, et al. [Gaucher disease in Latin America. A report from the Gaucher Disease International Registry and the Latin American Group for Gaucher disease]. Medicina (B Aires) 2012;72:273-282.
13. Fairley C, Zimran A, Phillips M, et al. Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher registry. J Inherit Metab Dis 2008;31:738-744.
14. Jeong SY, Park SJ, Kim HJ. Clinical and genetic characteristics of korean patients with Gaucher disease. Blood Cells Mol Dis 2011;46:11-14.
15. Eto Y, Ida H. Clinical and molecular characteristics of Japanese Gaucher disease. Neurochem Res 1999;24:207-211.
16. Weinreb NJ, Deegan P, Kacena KA, et al. Life expectancy in Gaucher disease type 1. Am J Hematol 2008;83:896-900.
17. Rosenbloom BE, Weinreb NJ, Zimran A, et al. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 2005;105:4569-4572.
18. Rosenbloom B, Balwani M, Bronstein JM, et al. The incidence of parkinsonism in patients with type 1 Gaucher disease: Data from the ICGG Gaucher Registry. Blood Cells Mol Dis 2011;46:95-102.
19. Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112-119.
20. Andersson HC, Charrow J, Kaplan P, et al. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med 2005;7:105-110.
21. Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004;41:4-14.
22. Cox TM, Aerts JM, Belmatoug N, et al. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis 2008;31:319-336.
23. Weinreb N, Taylor J, Cox T, et al. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Am J Hematol 2008;83:890-895.
24. Grabowski GA, Kacena K, Cole JA, et al. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet Med 2009;11:92-100.
25. Hollak CE, Belmatoug N, Cole JA, et al. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years. Br J Haematol 2012;158:528-538.
26. Drelichman G, Fernandez Escobar N, Basack N, et al. Gaucher disease in Argentina: report from the International Collaborative Gaucher Group (ICGG) Gaucher Registry and the Argentinian group for diagnosis and treatment of Gaucher disease. Hematologia (Supplement for Gaucher Disease) 2013;17:4-16.
27. Kaplan P, Mazur A, Manor O, et al. Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr 1996;129:149-153.
28. Kaplan P, Andersson HC, Kacena KA, Yee JD. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 2006;160:603-608.
29. Andersson H, Kaplan P, Kacena K, Yee J. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 2008;122:1182-1190.
30. Grabowski GA, Andria G, Baldellou A, et al. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr 2004;163:58-66.
31. Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004;163:67-75.
32. Charrow J, Andersson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatrics 2004;144:112-120.
33. Kaplan P, Baris H, De Meirleir L, et al. Revised recommendations for the management of Gaucher disease in children. Eur J Pediatr 2012;172:447-458.
34. Camelo JS, Drelichman GG, Kerstenetzky MM, et al. Long-term effect of imiglucerase in latin american children with Gaucher disease type 1: lessons from the International Collaborative Gaucher Group Gaucher Registry. BMC Hematol 2014;14:10
35. Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B. Skeletal aspects of Gaucher disease: A review. Br J Radiol 2002;75(Suppl 1):A2-A12.
36. Mistry PK, Weinreb NJ, Kaplan P, et al. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults. Blood Cells Mol Dis 2011;46:66-72.
37. Poll LW, Maas M, Terk MR, et al. Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol 2002;75(Suppl 1):A25-A36.
38. Charrow J, Dulisse B, Grabowski GA, Weinreb NJ. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 2007;71:205-211.
39. Wenstrup RJ, Kacena KA, Kaplan P, et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 2007; 22:119-126.
40. Mistry PK, Deegan P, Vellodi A, et al. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol 2009;147:561-570.
41. Khan A, Hangartner T, Weinreb NJ, et al. Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease - a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. J Bone Miner Res 2012;27:1839-1848.
42. Tylki-Szymanska A, Vellodi A, El-Beshlawy A, et al. Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry. J Inherit Metab Dis 2010;33:339-346.
43. Mistry P, Kolodny E, Anna T-S, et al. E. Phenotypic spectrum of hematological and visceral disease in type 3 Gaucher disease and response to imiglucerase therapy: preliminary analysis from the ICGG Gaucher Registry. Mol Gen Metab 2012;105:s46-s47.
44. Cole JA, Taylor JS, Hangartner TN, et al. Reducing selection bias in case-control studies from rare disease registries. Orphanet J Rare Dis 2011;6:61.